The immune systems of cancer patients are highly disrupted, with those who have a higher number of immune cells in their blood having a better survival rate, finds a new study that uses a pioneering ...

A COVID-19 diagnosis is no longer as frightening as it used to be, thanks to developments in treatment choices. However, a ...

During a Case-Based Roundtable® event, Nitin Jain, MD, and participants discussed treating a patient with CLL after ...

A new international study has found that a simple tablet treatment could improve survival rates for people with chronic ...

Acalabrutinib–Venetoclax improves progression-free survival and reduces disease progression in untreated chronic lymphocytic ...

An international study of over 800 chronic lymphocytic leukemia (CLL) patients found that an all-tablet therapy of ...

The degree of chronic lymphocytic leukemia ... binding to MEACs, cells were stained with 25 μg/ml normal human serum IgM (I8260; Sigma; 2 different lots), umbilical cord blood IgM (6 anonymous ...

Ibrutinib normalizes RBC aggregation in CLL, potentially reducing thrombotic risks by mitigating blood flow complications. Obinutuzumab/venetoclax combination does ...

This cancer affects immature cells in the immune system called prolymphocytes, which usually develop into white blood cells called lymphocytes. In B-PLL, B-lymphocytes grow and divide excessively ...

1Center for Advancement of Blood Cancer Therapies, Icahn School of Medicine at Mount Sinai, New York, New York. 2Black Family Stem Cell Institute, Institute for Regenerative Medicine, Icahn School of ...